Compounded GLP-1 drugs often come in multidose vials that require patients to measure their own medication, unlike the prefilled pens used for FDA-approved drugs
GLP-1 agonists and GIP antagonists GIP antagonism is also a potential obesity treatment as in preclinical studies improved the metabolic profile and reduced food intake [54,55,56]
Neurosci Biobehav Rev 120:470478
As a dual GIP/GLP-1 receptor agonist, it works by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying
Adding cagrilintide theoretically provides additional satiety signaling through the amylin pathway, potentially pushing total weight loss beyond 30%
Clinical studies report an average 15% to 21% drop in body weight after a little over one year of treatment